{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:24:44Z","timestamp":1792211084153,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognosis of patients with peritoneal metastasis (PM) from gastric cancer or adenocarcinoma of the esophagogastric junction (EGJ) remains poor. Diagnostic laparoscopy plays a key role in evaluating the extent of PM, facilitating accurate Peritoneal Cancer Index (PCI) assessment. However, the extent to which systemic therapy alters the PCI and whether such changes are reflected in PCI dynamics remains insufficiently understood. This study aimed to evaluate the effect of systemic therapy on the PCI in patients with synchronous PM and to identify clinical and pathological factors associated with PCI development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>In this retrospective analysis, 69 patients undergoing laparoscopic or open surgical exploration for PCI assessment prior to and following systemic treatment were evaluated. The primary outcome measure was the binary outcomes of decrease and increase of the PCI, and the influence of age, sex, tumor grading, presence of signet ring cells, type of systemic treatment, and tumor localization was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The PCI was higher in 56.5% of patients and stable or lower in 43.5%. High tumor grading (G3) was significantly associated with increasing PCI values (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002) despite systemic treatment. No statistically significant effects were observed for sex, age, signet ring cells, or tumor localization although estimated odds ratios using multiple regression analysis may suggest the presence of potential associations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Laparoscopy is essential for the assessment of peritoneal tumor burden. There is no uniform macroscopic response of PM to systemic therapy. Tumor grading might represent a relevant prognostic factor for PCI response to systemic therapy, which should be addressed in future investigations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20613-4","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:00:15Z","timestamp":1790377215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Chemotherapy in Patients with Synchronous Peritoneal Metastasis from Gastric and Esophagogastric Junction Cancers Has No Uniform Effect on the Peritoneal Cancer Index"],"prefix":"10.1245","author":[{"given":"Sarah","family":"Kalmbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Blumenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Yurttas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"3","key":"20613_CR1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622\u20138.","journal-title":"Int J Cancer."},{"issue":"3","key":"20613_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"20613_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.4251\/wjgo.v12.i5.569","volume":"12","author":"R Yarema","year":"2020","unstructured":"Yarema R, Ohorchak M, Hyrya P, et al. Gastric cancer with peritoneal metastases: Efficiency of standard treatment methods. World J Gastrointest Oncol. 2020;12(5):569\u201381.","journal-title":"World J Gastrointest Oncol."},{"key":"20613_CR4","doi-asserted-by":"crossref","unstructured":"Manzanedo I, Pereira F, Perez-Viejo E et al. Gastric cancer with peritoneal metastases: current status and prospects for treatment. Cancers (Basel) 2023; 15(6).","DOI":"10.3390\/cancers15061777"},{"issue":"2","key":"20613_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, K\u00f6nigsrainer A, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42(2):146\u201356.","journal-title":"J Clin Oncol."},{"issue":"44","key":"20613_CR6","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.3748\/wjg.v30.i44.4709","volume":"30","author":"YX Huang","year":"2024","unstructured":"Huang YX, He HY, Chen K, et al. Prognostic impact and reasons for variability by tumor location in gastric cancer. World J Gastroenterol. 2024;30(44):4709\u201324.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"20613_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"20613_CR8","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s00330-019-06524-x","volume":"30","author":"I van\u2019t Sant","year":"2020","unstructured":"van\u2019t Sant I, Engbersen MP, Beets-Tan RGH, et al. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur Radiol. 2020;30(6):3101\u201312.","journal-title":"Eur Radiol."},{"issue":"suppl 5","key":"20613_CR9","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38\u201349.","journal-title":"Ann Oncol"},{"key":"20613_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.suronc.2020.02.010","volume":"33","author":"M Leimkuhler","year":"2020","unstructured":"Leimkuhler M, de Haas RJ, Pol VEH, et al. Adding diagnostic laparoscopy to computed tomography for the evaluation of peritoneal metastases in patients with colorectal cancer: a retrospective cohort study. Surg Oncol. 2020;33:135\u201340.","journal-title":"Surg Oncol"},{"issue":"4","key":"20613_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1245\/s10434-019-07957-w","volume":"27","author":"J Hentzen","year":"2020","unstructured":"Hentzen J, Constansia RDN, Been LB, et al. Diagnostic laparoscopy as a selection tool for patients with colorectal peritoneal metastases to prevent a non-therapeutic laparotomy during cytoreductive surgery. Ann Surg Oncol. 2020;27(4):1084\u201393.","journal-title":"Ann Surg Oncol"},{"key":"20613_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res"},{"issue":"4","key":"20613_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/00031348211048819","volume":"88","author":"DN Hanna","year":"2022","unstructured":"Hanna DN, Ghani MO, Hermina A, et al. Diagnostic laparoscopy in patients with peritoneal carcinomatosis is safe and does not delay cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am Surg. 2022;88(4):698\u2013703.","journal-title":"Am Surg"},{"issue":"5","key":"20613_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1245\/s10434-015-4958-5","volume":"23","author":"RA Marmor","year":"2016","unstructured":"Marmor RA, Kelly KJ, Lowy AM, et al. Laparoscopy is safe and accurate to evaluate peritoneal surface metastasis prior to cytoreductive surgery. Ann Surg Oncol. 2016;23(5):1461\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"20613_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1470-2045(04)01425-1","volume":"5","author":"O Glehen","year":"2004","unstructured":"Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5(4):219\u201328.","journal-title":"Lancet Oncol"},{"key":"20613_CR16","doi-asserted-by":"crossref","unstructured":"Jain AJ, Badgwell BD. Current evidence for the use of HIPEC and cytoreductive surgery in gastric cancer metastatic to the peritoneum. J Clin Med 2023; 12(20).","DOI":"10.3390\/jcm12206527"},{"key":"20613_CR17","doi-asserted-by":"crossref","unstructured":"Horvath P, Yurttas C, Beckert S et al. Twelve-year single center experience shows safe implementation of developed peritoneal surface malignancy treatment protocols for gastrointestinal and gynecological primary tumors. Cancers (Basel) 2021; 13(10).","DOI":"10.3390\/cancers13102471"},{"key":"20613_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"DF Dubois","year":"1916","unstructured":"Dubois DF. A formula to estimate the approximate surface area if height and body mass be known. Arch Intern Med. 1916;17:863\u201371.","journal-title":"Arch Intern Med"},{"issue":"1","key":"20613_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27\u201338.","journal-title":"Biometrika"},{"issue":"1","key":"20613_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033323","volume":"10","author":"L Lou","year":"2020","unstructured":"Lou L, Wang L, Zhang Y, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. BMJ Open. 2020;10(1):e033323.","journal-title":"BMJ Open"},{"key":"20613_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1477-7819-12-270","volume":"12","author":"TT Jayakrishnan","year":"2014","unstructured":"Jayakrishnan TT, Zacharias AJ, Sharma A, et al. Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). World J Surg Oncol. 2014;12:270.","journal-title":"World J Surg Oncol"},{"key":"20613_CR22","doi-asserted-by":"crossref","unstructured":"Cardona K, Zhou Q, Gnen M et al. Role of repeat staging laparoscopy in locoregionally advanced gastric cancer after completion of neoadjuvant therapy. J Clin Oncol 2012; 30(4).","DOI":"10.1200\/jco.2012.30.4_suppl.11"},{"issue":"10184","key":"20613_CR23","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"23","key":"20613_CR24","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028\u201340.","journal-title":"J Clin Oncol"},{"issue":"13","key":"20613_CR25","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1245\/s10434-021-10157-0","volume":"28","author":"L Marano","year":"2021","unstructured":"Marano L, Marrelli D, Sammartino P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with synchronous peritoneal metastases: multicenter study of \u201cItalian Peritoneal Surface Malignancies Oncoteam-SICO.\u201d Ann Surg Oncol. 2021;28(13):9060\u201370.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"20613_CR26","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1245\/s10434-012-2465-5","volume":"19","author":"A Sommariva","year":"2012","unstructured":"Sommariva A, Zagonel V, Rossi CR. The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2012;19(12):3737\u201344.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"20613_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/jso.21069","volume":"98","author":"TD Yan","year":"2008","unstructured":"Yan TD, Morris DL, Shigeki K, et al. Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol. 2008;98(4):224\u20137.","journal-title":"J Surg Oncol"},{"issue":"13","key":"20613_CR28","doi-asserted-by":"publisher","first-page":"8560","DOI":"10.1245\/s10434-024-16035-9","volume":"31","author":"A Bhatt","year":"2024","unstructured":"Bhatt A, Villeneuve L, Sardi A, et al. Correlation of morphological appearance of peritoneal lesions at laparotomy and disease at pathological assessment in patients undergoing cytoreductive surgery for peritoneal malignancy: results of phase I of the PRECINCT study in 707 patients. Ann Surg Oncol. 2024;31(13):8560\u201371.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"20613_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00423-022-02455-2","volume":"407","author":"C Yurttas","year":"2022","unstructured":"Yurttas C, \u00dcberr\u00fcck L, Nadiradze G, et al. Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis. Langenbecks Arch Surg. 2022;407(4):1655\u201363.","journal-title":"Langenbecks Arch Surg."},{"issue":"6","key":"20613_CR30","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1245\/s10434-026-19344-3","volume":"33","author":"A Bhatt","year":"2026","unstructured":"Bhatt A, Sharma V, Pawar A, et al. MORPHology and inter-observer variation in peritoneal disease assessment among Expert peritoneal malignancy sUrgeonS: the MORPHEUS study. Ann Surg Oncol. 2026;33(6):5726\u201338.","journal-title":"Ann Surg Oncol"},{"key":"20613_CR31","doi-asserted-by":"crossref","unstructured":"Yurttas C, Horvath P, Fischer I et al. Fluorescence-guided laparoscopy after oral hypericin administration for staging of locally advanced gastric cancer-a pilot study. J Clin Med 2024; 13(8).","DOI":"10.3390\/jcm13082422"},{"issue":"7","key":"20613_CR32","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1245\/s10434-014-3487-y","volume":"21","author":"H Nadeem","year":"2014","unstructured":"Nadeem H, Jayakrishnan TT, Groeschl RT, et al. Cost effectiveness of routine laparoscopic ultrasound for assessment of resectability of gallbladder cancer. Ann Surg Oncol. 2014;21(7):2413\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"20613_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ejso.2005.01.009","volume":"31","author":"C Pomel","year":"2005","unstructured":"Pomel C, Appleyard TL, Gouy S, et al. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31(5):540\u20133.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"20613_CR34","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1245\/s10434-017-5805-7","volume":"24","author":"I Nassour","year":"2017","unstructured":"Nassour I, Fullington H, Hynan LS, et al. The yield of staging laparoscopy in gastric cancer is affected by racial and ethnic differences in disease presentation. Ann Surg Oncol. 2017;24(7):1787\u201394.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"20613_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/jso.25094","volume":"118","author":"CA Thiels","year":"2018","unstructured":"Thiels CA, Grotz TE, Fournier K, et al. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018;118(1):61\u20137.","journal-title":"J Surg Oncol."},{"key":"20613_CR36","doi-asserted-by":"crossref","unstructured":"Akay O, Guler M, Sevik HO et al. The impact of gastric anatomical subdivisions on the response to neoadjuvant chemotherapy in gastric cancer. Cancer Biother Radiopharm 2025.","DOI":"10.1177\/10849785251389350"},{"issue":"1","key":"20613_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s13277-012-0571-4","volume":"34","author":"XJ Wu","year":"2013","unstructured":"Wu XJ, Yuan P, Li ZY, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol. 2013;34(1):463\u20139.","journal-title":"Tumour Biol"},{"key":"20613_CR38","doi-asserted-by":"crossref","unstructured":"Chicago Consensus Working G. The Chicago consensus on peritoneal surface malignancies: management of gastric metastases. Ann Surg Oncol 2020; 27(6):1768\u20131773.","DOI":"10.1245\/s10434-020-08320-0"},{"issue":"1","key":"20613_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Yu W, Xie F, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8.","journal-title":"Nat Commun"},{"issue":"10294","key":"20613_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"11","key":"20613_CR41","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"10418","key":"20613_CR42","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208.","journal-title":"Lancet"},{"issue":"10389","key":"20613_CR43","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"issue":"8","key":"20613_CR44","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat Med"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20613-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20613-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20613-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:00:18Z","timestamp":1790377218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20613-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":44,"alternative-id":["20613"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20613-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"29 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interests or financial ties to disclose.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of T\u00fcbingen, University Ethics Committee (protocol code 297\/2024BO2 and date of approval 16 August 2024).","order":2,"name":"Ethics","label":"Institutional Review Board Statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}